ResearcherAmity UniversityActive in the last 2 years
Gouri Pandya
Matched on OpenAlex author ID A5079494307. Sources: OpenAlex.
Their work
- Papers
- 3 (first author 1, last author 0)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 3
2020: 1 paper · 2021: none · 2022: none · 2023: none · 2024: none · 2025: 1 paper · 2026: 1 paper
Papers 3
- SNHG10 promotes tumorigenesis through the EGFR/AKT/ERK/mTOR and miR-150-5p/VEGF-A axis, along with gemcitabine resistance in pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41420-026-03040-y↗
- Anticancer and therapeutic efficacy of XPO1 inhibition in pancreatic ductal adenocarcinoma through DNA damage and modulation of miR-193b/KRAS/LAMC2/ERK/AKT sig… First author DOI 10.1016/j.lfs.2024.123364↗
- The implication of long non-coding RNAs in the diagnosis, pathogenesis and drug resistance of pancreatic ductal adenocarcinoma and their possible therapeutic p… Co-author DOI 10.1016/j.bbcan.2020.188423↗
Closest collaborators
The 3 strongest of 3 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Manoj Garg · 3 shared papers, 2020–2026 · strength 0.66
- Paper SNHG10 promotes tumorigenesis through the EGFR/AKT/ERK/mTOR and miR-150-5p/VEGF-A axis, along with gemcitabine resistan… DOI 10.1038/s41420-026-03040-y↗
- Paper Anticancer and therapeutic efficacy of XPO1 inhibition in pancreatic ductal adenocarcinoma through DNA damage and modul… DOI 10.1016/j.lfs.2024.123364↗
- Paper The implication of long non-coding RNAs in the diagnosis, pathogenesis and drug resistance of pancreatic ductal adenoca… DOI 10.1016/j.bbcan.2020.188423↗
- Anuradha Kirtonia · 2 shared papers, 2020–2025 · strength 0.40
- Paper Anticancer and therapeutic efficacy of XPO1 inhibition in pancreatic ductal adenocarcinoma through DNA damage and modul… DOI 10.1016/j.lfs.2024.123364↗
- Paper The implication of long non-coding RNAs in the diagnosis, pathogenesis and drug resistance of pancreatic ductal adenoca… DOI 10.1016/j.bbcan.2020.188423↗
- Rajender K. Motiani · 1 shared paper, 2026 · strength 0.26
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.